Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.18
23.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
Accounts Receivables
Catalyst Pharmaceuticals Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
Accounts Receivables
$57.2m
|
CAGR 3-Years
109%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Receivables
$11.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Receivables
$4.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Receivables
$7.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Receivables
$1.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
32%
|
CAGR 10-Years
31%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Receivables
$6.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
Catalyst Pharmaceuticals Inc
Glance View
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company is headquartered in Coral Gables, Florida and currently employs 76 full-time employees. The company went IPO on 2006-11-08. The firm is focused on in-licensing, developing and commercializing medicines for patients living with rare diseases. The firm operates through the development and commercialization of drug products. The firm is developing a pipeline of medicines for other rare diseases. The firm's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse contains the phosphate salt of amifampridine. The firm's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Its wholly owned subsidiary is Catalyst Pharmaceuticals Ireland, Ltd.
See Also
What is Catalyst Pharmaceuticals Inc's Accounts Receivables?
Accounts Receivables
57.2m
USD
Based on the financial report for Jun 30, 2024, Catalyst Pharmaceuticals Inc's Accounts Receivables amounts to 57.2m USD.
What is Catalyst Pharmaceuticals Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
41%
Over the last year, the Accounts Receivables growth was 34%. The average annual Accounts Receivables growth rates for Catalyst Pharmaceuticals Inc have been 109% over the past three years , 41% over the past five years .
You don't have any saved screeners yet
